Cellectis
  • About
    Our mission
    Governance
    Partners
  • Science
    Our Genome Engineering Platform
    TALEN® Technology
    In-House Manufacturing
  • Pipeline
    Product Candidates
  • Investors
    IR Overview
    News
    • Press releases
    • Events and Webcasts
    Presentations
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    Corporate Governance
    • Board of Directors
    • Executive Committee
    • External Auditors
    • Governance Documents
    • General meetings
    Financial Information
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    Shareholders Services
    • IR Inquiries
    • IR FAQ
  • Careers
    Our culture
    Job opportunities
  • Contact us
LinkedinX FR
› Investors › Scientific publications
  • About
    • Our mission
    • Governance
    • Partners
  • Science
    • Our Genome Engineering Platform
    • TALEN® Technology
    • In-House Manufacturing
  • Pipeline
    • Product Candidates
  • Investors
    • IR Overview
    • News
      • Press releases
      • Events and Webcasts
    • Presentations
      • Corporate presentations
      • Scientific presentations
      • Scientific publications
    • Corporate Governance
      • Board of Directors
      • Executive Committee
      • External Auditors
      • Governance Documents
      • General meetings
    • Financial Information
      • SEC filings
      • Financial statements
      • Voting Rights & Share Capital
      • Stock information
    • Shareholders Services
      • IR Inquiries
      • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
  • Contact us
FR
LinkedinX

Scientific publications

All 2025 2024 2023 2022 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2003 2002
20
Nov 2017
21:36 E.S.T.

Fine and predictable tuning of TALEN gene editing targeting for improved T-cell adoptive immunotherapy

Anne-Sophie Gautron, Alexandre Juillerat, Valérie Guyot, Jean-Marie Filhol, Emilie Dessez, Aymeric Duclert, Philippe Duchateau and Laurent Poirot
Molecular Therapy - Nucleic Acids Volume 9, December 15, 2017
Read more
30
Jan 2017
17:37 E.S.T.

Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells

Francesca Stillitano, Jens Hansen, Chi-Wing Kong, Ioannis Karakikes, Christian Funck-Brentano, Lin Geng, Stuart Scott, Stephan Reynier, Ma Wu, Yannick Valogne, Carole Desseaux, Joe-Elie Salem, Dorota Jeziorowska, Noël Zahr, Ronald Li, Ravi Iyengar, Roger J Hajjar, Jean-Sébastien Hulot
Elife. 2017 Jan 30
Read more
20
Jan 2017
13:05 E.S.T.

An oxygen sensitive self-decision making engineered CAR T-cell

Alexandre Juillerat, Alan Marechal, Jean Marie Filhol, Yannick Valogne, Julien Valton, Aymeric Duclert, Philippe Duchateau and Laurent Poirot
Scientific Reports 7, Article number: 39833 (2017) doi:10.1038/srep39833
Read more

Media contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US
cellectis

Clinical-stage biotech · Dual-listed on Nasdaq (CLLS) and Euronext Growth (ALCLS).
Paris · New York · Raleigh.

  • ABOUT
    • Our mission
    • Governance
    • Partners
  • SCIENCE
    • In-House Manufacturing
    • PulseAgile Technology
    • TALEN® Technology
    • Understanding Gene Editing
  • PIPELINE
    • Product Candidates
    • BALLI-01 Trial
    • NATHALI-01 Trial
    • Patients
  • INVESTORS
    • Events
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    • Governance Documents
    • ESG report
    • Shareholders Meetings
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    • PDMR Notifications
    • IR Inquiries
    • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
© 2026 Cellectis — All rights reserved
  • Legal notice
  • Community Guidelines